Since there is no cure for AD, drug repurposing studies have been intensely searching to identify existing drugs that could be repositioned to treat AD. As pharmaceutical development process is both time-consuming and costly, drug repurposing provides a chance to accelerate it by exploring the AD-related effects of agents approved for other disorders. These drugs have established safety profiles, pharmacokinetic description, formulations, dosages, and manufacturing procedures. Recently, in silico pharmacology has been widely applied and various computer applications including machine learning and artificial intelligence approaches have been explored in identifying potential drugs for repurposing to AD. Drug repurposing has already been attempted in AD with various methodologies applied and several clinical trials are currently evaluating drug-repurposing candidates for AD. 207, 217-219 Fifty widely discussed drugs for AD repurposing are summarized in Table . We identified over 700 documents in CAS Content Collection discussing drug repurposing for AD. The number of AD drug repurposing publications increased dramatically over the last decade -from 13 documents in 2013 to 147 in 2023 (Figure , Inset). The distribution of the considered potential repurposed drug classes with respect to their original disease targets according to the CAS Content Collection is illustrated in Figure . Predictably, drugs for repurposing to AD are most often searched within the pool of nervous system agents. Anticancer drugs, metabolic agents, and immunomodulators are also between the hopeful drugs for repurposing to AD (Figure ).